Janux Therapeutics (NASDAQ:JANX) Earns Outperform Rating from William Blair

William Blair reiterated their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a report released on Friday,RTT News reports.

A number of other equities analysts have also recently issued reports on JANX. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Scotiabank raised their price objective on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday, December 4th. UBS Group started coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price on the stock. BTIG Research raised their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Finally, Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Trading Down 8.0 %

JANX stock opened at $46.76 on Friday. The firm has a 50-day moving average price of $54.26 and a 200-day moving average price of $48.20. Janux Therapeutics has a 12 month low of $7.79 and a 12 month high of $71.71. The stock has a market capitalization of $2.45 billion, a P/E ratio of -39.97 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business’s quarterly revenue was down 82.6% compared to the same quarter last year. As a group, equities analysts predict that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Andrew Hollman Meyer sold 13,334 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares of the company’s stock, valued at $4,507,788.32. This trade represents a 13.97 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of Janux Therapeutics stock in a transaction on Thursday, October 17th. The shares were sold at an average price of $50.02, for a total transaction of $92,186.86. Following the completion of the sale, the insider now owns 6,371 shares of the company’s stock, valued at $318,677.42. This represents a 22.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,177 shares of company stock worth $6,162,207. Company insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Large investors have recently made changes to their positions in the company. Franklin Resources Inc. boosted its holdings in Janux Therapeutics by 64.5% in the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock worth $937,000 after acquiring an additional 7,442 shares in the last quarter. Virtu Financial LLC raised its position in shares of Janux Therapeutics by 48.0% during the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after purchasing an additional 2,419 shares during the period. Neo Ivy Capital Management bought a new position in shares of Janux Therapeutics in the 3rd quarter worth $940,000. Geode Capital Management LLC grew its position in Janux Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after purchasing an additional 38,490 shares during the period. Finally, Barclays PLC increased its stake in Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after purchasing an additional 144,883 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.